Compass Therapeutics (CMPX) Accumulated Depreciation & Amortization (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Accumulated Depreciation & Amortization for 3 consecutive years, with $6.6 million as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 4.34% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, up 4.34% year-over-year, with the annual reading at $6.6 million for FY2025, 4.34% up from the prior year.
- Accumulated Depreciation & Amortization hit $6.6 million in Q4 2025 for Compass Therapeutics, roughly flat from $6.6 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.7 million in Q3 2024 to a low of $5.8 million in Q1 2023.
- Historically, Accumulated Depreciation & Amortization has averaged $6.4 million across 3 years, with a median of $6.5 million in 2024.
- Biggest five-year swings in Accumulated Depreciation & Amortization: grew 11.44% in 2024 and later fell 1.43% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $6.3 million in 2023, then rose by 1.5% to $6.4 million in 2024, then grew by 4.34% to $6.6 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for CMPX at $6.6 million in Q4 2025, $6.6 million in Q3 2025, and $6.6 million in Q2 2025.